MOBERG DERMA INITIATES PHASE II TRIAL WITH LIMTOP FOLLOWING POSITIVE PHASE I RESULTS

The German Federal Institute for Drugs and Medical Devices (BfArM) has granted
Moberg Derma approval to initiate a clinical phase II trial for Limtop. The aim
is to evaluate the efficacy and safety of three different dose regimens of
Limtop in a study involving 96 patients with Actinic Keratosis (AK) on the head
or face. The results are expected in the first half of 2013. The approval was
granted following positive results from a phase I study on 30 healthy volunteers
who were treated daily for 21 days. No serious treatment-related adverse events
were observed.
Limtop is an innovative formulation of imiquimod to treat actinic keratosis,
genital warts and basal cell cancer. The objective is a product with short
treatment duration, an improved safety profile and an efficacy similar to or
better than that of competing preparations.

”Limtop has the potential to make
a real difference for many patients who currently suffer significant side
effects, and we look forward to evaluate this novel formulation in actinic
keratosis patients”, says Peter Wolpert, CEO and founder of Moberg
Derma.

About Limtop and actinic keratosis
Limtop is based on a patent
-pending formulation of imiquimod, a proven compound, which results in an
optimal dose of the active substance being delivered into the skin. The
company's preclinical results show that Limtop has a significantly better
capacity than existing preparations to transport the active substance to the
target tissue in the skin. Actinic keratosis is sun damage to the skin that is
characterised by thickening of the horny layer of the epidermis. The condition
has become more common as a result of changed lifestyle and increased exposure
to strong sunlight. Actinic keratosis can develop into squamous cell carcinoma
and should thus be treated. Prevalence varies, as fair-skinned individuals are
affected more. In populations in the northern hemisphere the prevalence is
reported as being between 11% and 25%.

About this information
Moberg Derma
discloses the information provided herein pursuant to the Securities Markets Act
and/or the Financial Instruments Trading Act. The information was submitted for
publication on at 8:30 am (CET) on May 2nd, 2012.
For further information, please contact:
Peter Wolpert, President and
CEO
Telephone: +46 8 522 307 00
Mobile: +46 735 71 35
E-mail:
peter.wolpert@mobergderma.se

Magnus Persson, IR
Mobile: +46 73-355 26 01
E
-mail: magnus.persson@mobergderma.se
About Moberg Derma
Moberg Derma AB (publ), based in Stockholm, develops
patented topical pharmaceuticals for the treatment of common disorders through
the use of innovative drug delivery. The company’s products are based on proven
compounds, which reduce time to market, development costs and risk. Moberg
Derma’s first product Nalox™/Emtrix® - for nail disorders - became the Nordic
market leader directly after launch in autumn 2010 and international launch is
ongoing. The portfolio includes approved and launched products to projects in
the preclinical and clinical phase. The company began operations in Stockholm in
2006. The share of Moberg Derma is quoted on the Small Cap list of the NASDAQ
OMX Nordic Exchange Stockholm. For further information, please visit:
www.mobergderma.com